Literature DB >> 33894507

SAR insights into TET2 catalytic domain inhibition: Synthesis of 2-Hydroxy-4-Methylene-pentanedicarboxylates.

Anand D Tiwari1, Yihong Guan2, Dale R Grabowski2, Jaroslaw P Maciejewski3, Babal K Jha3, James G Phillips4.   

Abstract

The TET (Ten-Eleven Translocation) dioxygenase enzyme family comprising 3 members, TET1-3, play key roles in DNA demethylation. These processes regulate transcription programs that determine cell lineage, survival, proliferation, and differentiation. The impetus for our investigations described here is derived from the need to develop illuminating small molecule probes for TET enzymes with cellular activity and specificity. The studies were done so in the context of the importance of TET2 in the hematopoietic system and the preponderance of loss of function somatic TET2 mutations in myeloid diseases. We have identified that 2-hydroxy-4-methylene-pentanedicarboxylic acid 2a reversibly competes with the co-substrate α-KG in the TET2 catalytic domain and inhibits the dioxygenase activity with an IC50 = 11.0 ± 0.9 μM at 10 μM α-KG in a cell free system and binds in the TET2 catalytic domain with Kd = 0.3 ± 0.12 μM.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  2-Hydroxyglutarate; Dioxygenase; Enzyme inhibition; Epigenetic; TET; α-KG

Mesh:

Substances:

Year:  2021        PMID: 33894507      PMCID: PMC8171112          DOI: 10.1016/j.bmc.2021.116141

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.461


  33 in total

Review 1.  Eukaryotic cytosine methyltransferases.

Authors:  Mary Grace Goll; Timothy H Bestor
Journal:  Annu Rev Biochem       Date:  2005       Impact factor: 23.643

2.  2-difluoromethylene-4-methylenepentanoic acid, a paradoxical probe able to mimic the signaling role of 2-oxoglutaric acid in cyanobacteria.

Authors:  Xinjun Liu; Han Chen; Erik Laurini; Yang Wang; Valentina Dal Col; Paola Posocco; Fabio Ziarelli; Maurizio Fermeglia; Cheng-Cai Zhang; Sabrina Pricl; Ling Peng
Journal:  Org Lett       Date:  2011-05-05       Impact factor: 6.005

Review 3.  The Bump-and-Hole Tactic: Expanding the Scope of Chemical Genetics.

Authors:  Kabirul Islam
Journal:  Cell Chem Biol       Date:  2018-08-02       Impact factor: 8.116

4.  Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.

Authors:  Myunggon Ko; Yun Huang; Anna M Jankowska; Utz J Pape; Mamta Tahiliani; Hozefa S Bandukwala; Jungeun An; Edward D Lamperti; Kian Peng Koh; Rebecca Ganetzky; X Shirley Liu; L Aravind; Suneet Agarwal; Jaroslaw P Maciejewski; Anjana Rao
Journal:  Nature       Date:  2010-12-09       Impact factor: 49.962

5.  The ProteomeXchange consortium in 2020: enabling 'big data' approaches in proteomics.

Authors:  Eric W Deutsch; Nuno Bandeira; Vagisha Sharma; Yasset Perez-Riverol; Jeremy J Carver; Deepti J Kundu; David García-Seisdedos; Andrew F Jarnuczak; Suresh Hewapathirana; Benjamin S Pullman; Julie Wertz; Zhi Sun; Shin Kawano; Shujiro Okuda; Yu Watanabe; Henning Hermjakob; Brendan MacLean; Michael J MacCoss; Yunping Zhu; Yasushi Ishihama; Juan A Vizcaíno
Journal:  Nucleic Acids Res       Date:  2020-01-08       Impact factor: 16.971

6.  Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease.

Authors:  Siddhartha Jaiswal; Pradeep Natarajan; Alexander J Silver; Christopher J Gibson; Alexander G Bick; Eugenia Shvartz; Marie McConkey; Namrata Gupta; Stacey Gabriel; Diego Ardissino; Usman Baber; Roxana Mehran; Valentin Fuster; John Danesh; Philippe Frossard; Danish Saleheen; Olle Melander; Galina K Sukhova; Donna Neuberg; Peter Libby; Sekar Kathiresan; Benjamin L Ebert
Journal:  N Engl J Med       Date:  2017-06-21       Impact factor: 91.245

7.  A Therapeutic Strategy for Preferential Targeting of TET2 Mutant and TET-dioxygenase Deficient Cells in Myeloid Neoplasms.

Authors:  Yihong Guan; Anand D Tiwari; James G Phillips; Metis Hasipek; Dale R Grabowski; Simona Pagliuca; Priyanka Gopal; Cassandra M Kerr; Vera Adema; Tomas Radivoyevitch; Yvonne Parker; Daniel J Lindner; Manja Meggendorfer; Mohamed Abazeed; Mikkeal A Sekeres; Omar Y Mian; Torsten Haferlach; Jaroslaw P Maciejewski; Babal K Jha
Journal:  Blood Cancer Discov       Date:  2020-12-07

Review 8.  Tet Enzymes, Variants, and Differential Effects on Function.

Authors:  Philippa Melamed; Yahav Yosefzon; Cfir David; Anna Tsukerman; Lilach Pnueli
Journal:  Front Cell Dev Biol       Date:  2018-03-05

Review 9.  Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease.

Authors:  Christina K Ferrone; Mackenzie Blydt-Hansen; Michael J Rauh
Journal:  Int J Mol Sci       Date:  2020-01-17       Impact factor: 5.923

10.  Context dependent effects of ascorbic acid treatment in TET2 mutant myeloid neoplasia.

Authors:  Yihong Guan; Edward F Greenberg; Metis Hasipek; Shi Chen; Xiaochen Liu; Cassandra M Kerr; Daniel Gackowski; Ewelina Zarakowska; Tomas Radivoyevitch; Xiaorong Gu; Belinda Willard; Valeria Visconte; Hideki Makishima; Aziz Nazha; Mridul Mukherji; Mikkael A Sekeres; Yogen Saunthararajah; Ryszard Oliński; Mingjiang Xu; Jaroslaw P Maciejewski; Babal K Jha
Journal:  Commun Biol       Date:  2020-09-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.